Cannabinoid Receptor II peptide (ab45941)
Key features and details
- Purity: > 90% HPLC
- Suitable for: Blocking, WB
Description
-
Product name
Cannabinoid Receptor II peptide
See all Cannabinoid Receptor II proteins and peptides -
Purity
> 90 % HPLC. -
Accession
-
Animal free
No -
Nature
Synthetic -
-
Species
Human
-
-
Description
Human Cannabinoid Receptor II peptide
Specifications
Our Abpromise guarantee covers the use of ab45941 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Blocking
Western blot
-
Form
Lyophilized -
Additional notes
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Store at -20°C.
Information available upon request.
General Info
-
Alternative names
- Cannabinoid receptor 2
- Cannabinoid receptor 2 macrophage
- CB 2
see all -
Function
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis. -
Tissue specificity
Preferentially expressed in cells of the immune system with higher expression in B cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root glanglion sensory neurons (at protein level). -
Sequence similarities
Belongs to the G-protein coupled receptor 1 family. -
Post-translational
modificationsConstitutively phosphorylated on Ser-352; phosphorylation increases cell internalization and desensitizes the receptor. -
Cellular localization
Cell membrane. Cell projection > dendrite. Perikaryon. Localizes to apical dendrite of pyramidal neurons. - Information by UniProt
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (5)
ab45941 has been referenced in 5 publications.
- Lah TT et al. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells 10:N/A (2021). PubMed: 33562819
- Ghosh S et al. The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss. Front Cell Neurosci 12:271 (2018). PubMed: 30186120
- Martín-Saldaña S et al. Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment. PLoS One 11:e0161954 (2016). PubMed: 27564061
- den Boon FS et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A 109:3534-9 (2012). WB . PubMed: 22331871
- Tyagi V et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181:1932-8 (2009). WB . PubMed: 19237176
